AKER - Akers Biosciences, Inc.
| Previous Close | 0.5653 |
| Open | 0.5600 |
| Bid | 0.5503 x 800 |
| Ask | 0.5800 x 800 |
| Day's Range | 0.5230 - 0.5700 |
| 52 Week Range | 0.5100 - 3.9200 |
| Volume | 76,663 |
| Avg. Volume | 226,104 |
| Market Cap | 6.986M |
| Beta (3Y Monthly) | -1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8360 |
| Earnings Date | Jun 30, 2019 - Jul 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.86 |
- Yahoo Finance Video•7 months ago
Apple shares down after cutting production orders for all three iphone models
Yahoo Finance's Julie Hyman highlights todays stocks on the move in midday trading.
- Markit•9 days ago
See what the IHS Markit Score report has to say about Akers Biosciences Inc.
Akers Biosciences Inc NASDAQ:AKERView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AKER is favorable, with net inflows of $694 million. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•last month
Akers Biosciences Reports Q1 2019 Earnings
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three months ended March 31, 2019. At March 31, 2019, Akers Bio had cash, restricted cash and marketable securities of $5.23 million. During the fourth quarter of 2018, the Board of Directors initiated a process to evaluate strategic alternatives to maximize shareholder value.
- American City Business Journals•3 months ago
As losses mount, medical device maker continues pursuit of 'strategic alternatives'
South Jersey medical device maker Akers Biosciences Inc. — which saw its sales cut in half last year — said it is continuing to evaluate 'strategic alternatives" that include looking at business combinations in alternative sectors such as cannabis related industries. “Our focus throughout the latter part of 2018 and into 2019 has been on streamlining the company’s operations, rightsizing human resources with a concentration on products which currently generate sales, cutting unnecessary corporate expense and resolving legacy issues," said Howard R. Yeaton, CEO and interim-CFO at Akers BioSciences (NASDAQ: AKER).
- GlobeNewswire•3 months ago
Akers Biosciences Reports Fiscal Year 2018 Earnings
Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the fiscal year ended December 31, 2018. At December 31, 2018, Akers Bio had cash, restricted cash and marketable securities of $5.96 million, which the Company reports is sufficient to fund its obligations into 2020. The process is ongoing and will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries.
- GlobeNewswire•4 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•6 months ago
4 Healthcare Stocks That Are Raising Eyebrows
CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.
- ACCESSWIRE•6 months ago
These 4 Healthcare Stocks Are Heating Up
CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy.
- GlobeNewswire•7 months ago
Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•7 months ago
This Tiny Biotech Firm Is Weighing An Entrance Into Cannabis
Akers Biosciences, Inc. (NASDAQ: AKER)'s stock was trending on Benzinga Pro Tuesday, with shares of the microcap trading on 40-percent higher than average volume. The stock's decline — it was down 11.7 percent at $1.54 at the time of publication Tuesday — follows the 42.28-percent jump the shares registered Monday following an announcement that the company could enter the cannabis industry. What Is Akers? Akers Biosciences develops and manufactures rapid screening and testing products for health care providers and consumers.
- ACCESSWIRE•7 months ago
Today’s Research Reports on Stocks to Watch: Akers Biosciences and Align Technology
NEW YORK, NY / ACCESSWIRE / November 20, 2018 / While Akers Biosciences shares were exploding on the news that the company is considering the cannabis industry, shares of Align Technology were plummeting on a pessimistic highlight of the company in the Wall Street Journal from over the weekend. Align Technology, Inc. Akers Biosciences, Inc. shares closed up 42.28% on Monday on tremendous trading volume of nearly 15.4 million shares traded.
- American City Business Journals•7 months ago
South Jersey medical device firm exploring cannabis industry combination
The Thorofare, N.J., company which began exploring "strategic alternatives" earlier this month has hired a legal advisor to advise it on potential business combinations in the cannabis industry.
- GlobeNewswire•7 months ago
Akers Biosciences Exploring Potential Business Combinations in Alternative Sectors Including Cannabis Industry
Akers Biosciences, Inc. (AKER) (AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, is pleased to provide an update on the process announced on November 7, 2018 to evaluate strategic alternatives to maximize shareholder value. The Company can now confirm that this process will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries. Members of the Company’s board have recently met with a number of companies in cannabis related industries at the MJBizCon conference in Las Vegas, Nevada.
- GlobeNewswire•7 months ago
Akers Biosciences Announces Q3 2018 Earnings
Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE,.
- American City Business Journals•7 months ago
South Jersey medical-device company exploring 'strategic alternatives'
Akers BioSciences is also implementing a one-for-eight reverse stock split to stay in compliance with NASDAQ listing requirements.
- GlobeNewswire•7 months ago
Akers Biosciences Announces Intention to Explore Strategic Alternatives to Maximize Shareholder Value
Akers Biosciences, Inc. (AKER) (AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces that the Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. This process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. The Company does not plan to disclose or comment on developments regarding the strategic review process until it is complete or further disclosure is deemed appropriate.
